The study focuses on adults with early polymyalgia rheumatica, a condition that causes pain and stiffness in the shoulders, hips, and neck. The investigational medication sarilumab is given as an injection every two weeks, together with a standard steroid called prednisone that is gradually reduced over a year.
The purpose of the study is to determine whether adding the injection to the steroid taper provides better and longer‑lasting remission than the steroid taper alone. Participants are randomly assigned to receive either the injection or a matching inactive substance, and neither the participants nor the study staff know which one is given. Over 52 weeks, participants continue the steroid at decreasing doses while attending regular check‑ins to monitor symptoms and safety.
The inactive substance used for comparison is a placebo, which looks the same as the active injection but does not contain the medication. Throughout the year, patients are evaluated for sustained remission, any flare‑ups, and overall well‑being using simple questionnaires and routine lab tests. Safety is closely watched for any side effects or unusual laboratory results.
Austria 
Belgium 
Czechia 
France 
Germany 
Greece 
Hungary 
Spain 
The Netherlands